MyFinsight
Home
Blog
About
Net product revenue
$261,280K
(-32.17%↓ Y/Y)
Interest income
$7,072K
(168.39%↑ Y/Y)
Net income
$75,431K
(-11.61%↓ Y/Y)
Other liabilities
$22,868K
(283.19%↑ Y/Y)
Canceled cashflow
$192,921K
Stock-based compensation
$9,335K
(-61.03%↓ Y/Y)
Intangible amortization
$5,961K
(-50.00%↓ Y/Y)
Other non-cash
expenses
$679K
(-27.15%↓ Y/Y)
Stock appreciation
rights market...
$241K
(319.09%↑ Y/Y)
Debt issuance costs
amortization
$147K
(-55.32%↓ Y/Y)
Depreciation
$7K
(-46.15%↓ Y/Y)
Net cash provided by
operating activities
$92,432K
(-18.43%↓ Y/Y)
Canceled cashflow
$22,237K
Cost of product sold
$63,191K
(-9.90%↓ Y/Y)
Research and development
$44,034K
(-32.55%↓ Y/Y)
Sales and marketing
$32,311K
(-42.70%↓ Y/Y)
Income tax expense
$17,834K
(-16.97%↓ Y/Y)
General and
administrative
$16,884K
(-55.81%↓ Y/Y)
Stock-based compensation
$9,576K
(-59.84%↓ Y/Y)
Depreciation and
amortization
$5,968K
(-50.00%↓ Y/Y)
Interest expense
$3,070K
(-58.97%↓ Y/Y)
Other segment items
$53K
(-99.66%↓ Y/Y)
Net (decrease)
increase in cash, cash...
-$39,629K
(-142.59%↓ Y/Y)
Canceled cashflow
$92,432K
Proceeds from maturities
and sales of...
$21,031K
(-48.63%↓ Y/Y)
Proceeds from exercised
options
$5,517K
(-18.90%↓ Y/Y)
Prepaid expenses and
other assets
$7,848K
(40.49%↑ Y/Y)
Trade payables
-$6,916K
(-147.51%↓ Y/Y)
Deferred taxes
-$3,203K
(70.33%↑ Y/Y)
Trade receivables
$2,773K
(-72.13%↓ Y/Y)
Inventory
$1,079K
(198.27%↑ Y/Y)
Amortization of premiums and
accretion of discounts on...
$418K
(-53.76%↓ Y/Y)
Net cash used in
investing activities
-$131,503K
(-663.35%↓ Y/Y)
Canceled cashflow
$21,031K
Net cash used in
financing activities
-$558K
(81.63%↑ Y/Y)
Canceled cashflow
$5,517K
Purchase of investment
securities
$152,534K
(254.47%↑ Y/Y)
Principal repayment of
long-term debt
$5,000K
(-33.33%↓ Y/Y)
Payments of employee
withholding taxes related to...
$1,075K
(-54.08%↓ Y/Y)
Back
Back
Cash Flow
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)
source: myfinsight.com